News articles about Nevro Corp. (NYSE:NVRO) have trended somewhat positive on Friday, according to Accern. The research group ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Nevro Corp. earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave news coverage about the medical equipment provider an impact score of 45.7167487730529 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

These are some of the news articles that may have impacted Accern Sentiment’s analysis:

Shares of Nevro Corp. (NYSE NVRO) opened at 83.74 on Friday. The company’s 50 day moving average price is $83.40 and its 200 day moving average price is $85.19. Nevro Corp. has a 52-week low of $65.82 and a 52-week high of $106.93. The company’s market capitalization is $2.47 billion.

Nevro Corp. (NYSE:NVRO) last posted its quarterly earnings data on Monday, August 7th. The medical equipment provider reported ($0.40) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.29) by $0.11. The business had revenue of $78.02 million during the quarter, compared to analyst estimates of $77.75 million. Nevro Corp. had a negative return on equity of 16.25% and a negative net margin of 14.33%. The firm’s revenue for the quarter was up 40.8% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.31) EPS. On average, analysts predict that Nevro Corp. will post ($1.16) EPS for the current year.

Several equities research analysts recently weighed in on NVRO shares. B. Riley lowered Nevro Corp. from a “buy” rating to a “neutral” rating and dropped their price target for the company from $108.00 to $85.00 in a research report on Tuesday, May 9th. Morgan Stanley lifted their price target on Nevro Corp. from $87.00 to $95.00 and gave the company an “overweight” rating in a research report on Tuesday, August 8th. Zacks Investment Research lowered Nevro Corp. from a “hold” rating to a “sell” rating in a research report on Thursday, May 11th. ValuEngine lowered Nevro Corp. from a “hold” rating to a “sell” rating in a research report on Wednesday, May 24th. Finally, BidaskClub lowered Nevro Corp. from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $100.57.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/08/18/nevro-corp-nvro-receives-media-impact-score-of-0-16.html.

In other news, Director Wilfred E. Jaeger sold 79,657 shares of the firm’s stock in a transaction on Wednesday, August 16th. The stock was sold at an average price of $82.74, for a total value of $6,590,820.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Andrew H. Galligan sold 7,000 shares of the firm’s stock in a transaction on Monday, August 14th. The stock was sold at an average price of $82.31, for a total value of $576,170.00. The disclosure for this sale can be found here. Insiders sold a total of 141,577 shares of company stock valued at $11,696,551 in the last three months. Insiders own 12.10% of the company’s stock.

About Nevro Corp.

Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Insider Buying and Selling by Quarter for Nevro Corp. (NYSE:NVRO)

Receive News & Stock Ratings for Nevro Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro Corp. and related stocks with our FREE daily email newsletter.